---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-067378"
form_type: "8-K"
ticker: "ATNM"
cik: "0001388320"
company_name: "Actinium Pharmaceuticals, Inc."
filed_at: "2022-10-31T23:59:59+00:00"
generated_at: "2026-06-22T21:29:36.887627+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Actinium's Iomab-B meets primary endpoint in Phase 3 SIERRA AML trial (p<0.0001)

## Summary
- Phase 3 SIERRA trial of Iomab-B in AML patients 55+ with active relapsed/refractory disease met primary endpoint of durable complete remission (dCR) at 6 months with p<0.0001.
- Iomab-B is a targeted radiotherapy conditioning regimen prior to bone marrow transplant; compared to conventional care with intent to transplant.
- Company to submit Biologics License Application (BLA) to FDA for approval of Iomab-B; additional SIERRA data expected by year-end 2022.
- CEO Sandesh Seth calls it a significant milestone; CMO Avinash Desai highlights statistical significance and increased access to BMT.

## SEC filing metadata
- accession: 0001213900-22-067378
- form_type: 8-K
- ticker: ATNM
- cik: 0001388320
- company_name: Actinium Pharmaceuticals, Inc.
- filed_at: 2022-10-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1388320/000121390022067378/0001213900-22-067378-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1388320/000121390022067378/ea167769-8k_actinium.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-067378
- JSON: https://secwatch.observer/filing/0001213900-22-067378.json
- Plain text: https://secwatch.observer/filing/0001213900-22-067378.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.